Vanguard Capital Management’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$31.4M Sell
13,239,670
-158,264
-1% -$223K ﹤0.01% 2154
2026
Q2
$22.5M Buy
13,397,934
+620,485
+5% +$902K ﹤0.01% 2379
2026
Q1
$16.9M Buy
+12,777,449
New +$22.9M ﹤0.01% 2442

Other funds holding PACB

Vanguard Capital Management's PACB Position: Q3 2026 in Review

Vanguard Capital Management reduced its Pacific Biosciences (PACB) stake by 1.2% in Q3 2026, selling an estimated $223K and leaving 13,239,670 shares worth $31.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2154.

Vanguard Capital Management first reported a position in PACB in Q1 2026 and has held it in 3 quarters since. 204 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

  • Vanguard Capital Management held 13,239,670 shares of Pacific Biosciences worth $31.4M as of Q3 2026.
  • Vanguard Capital Management sold 158,264 Pacific Biosciences shares in Q3 2026, an estimated $223K.
  • Pacific Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2154 holding.
  • Vanguard Capital Management first reported a position in Pacific Biosciences in Q1 2026 and has held it in 3 quarters since.
  • 204 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.